By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer

What breast cancer drugs are available in Canada

MedSearch

Generic Name

Ribociclib (plus fulvestrant)

Brand Name

Kisqali (plus fulvestrant)
HR+, HER2-
Stage IV (metastatic)
Targeted Therapy
Novartis
Oral Drug
Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, Ontario, Prince Edward Island, Quebec, Saskatchewan, Yukon
No
Listed on Provincial Drug Formulary

For: post-menopausal women

It is available as an initial endocrine therapy or following disease progression.
Ribociclib is also approved for use in combination with letrozole.
Ribociclib is also approved for use in combination with an aromatase inhibitor.

*Please Note: Ontario, Nova Scotia, New Brunswick, PEI and Newfoundland & Labrador have limited coverage for the cost of oral medications, forcing many patients to use private insurance or pay out of pocket. Check with your oncologist to see if you have coverage.

No

Health Canada Drug Monograph

FAQ's